...
首页> 外文期刊>Resuscitation. >Outcomes and healthcare-associated costs one year after intensive care-treated cardiac arrest
【24h】

Outcomes and healthcare-associated costs one year after intensive care-treated cardiac arrest

机译:经过重症监护治疗的心脏骤停后一年的结果和医疗保健相关费用

获取原文
获取原文并翻译 | 示例
           

摘要

BackgroundDespite the significant socioeconomic burden associated with cardiac arrest (CA), data on CA patients’ long-term outcome and healthcare-associated costs are limited. The aim of this study was to determine one-year survival, neurological outcome and healthcare-associated costs for ICU-treated CA patients. MethodsThis is a single-centre retrospective study on adult CA patients treated in Finnish tertiary hospital’s ICUs between 2005 and 2013. Patients’ personal identification number was used to crosslink data between several nationwide databases in order to obtain data on one-year survival, neurological outcome, and healthcare-associated costs. Healthcare-associated costs were calculated for every patient stratified by cardiac arrest location (OHCA?=?out-of-hospital cardiac arrest, IHCA?=?all in-hospital cardiac arrest, ICU-CA?=?in-ICU cardiac arrest) and initial cardiac rhythm. Cost-effectiveness was estimated by dividing total healthcare-associated costs for all patients from the respective group by the number of survivors and survivors with favourable neurological outcome. ResultsThe study population included 1,024 ICU-treated CA patients. The sum of costs for all patients was €50,847,540. At one-year after CA, 58% of OHCAs, 44% of IHCAs, and 39% of ICU-CAs were alive. Of one-year survivors 97% of OHCAs, 88% of IHCAs, and 93% of ICU-CAs had favourable neurological outcome. Effective cost per one-year survivor was €76,212 for OHCAs, €144,168 for IHCAs, and €239,468 for ICU-CAs. Effective cost per one-year survivor with favourable neurological outcome was €81,196 for OHCAs, €164,442 for IHCAs, and €257,207 for ICU-CAs. ConclusionsIn-ICU CA patients had the lowest one-year survival with the effective cost per survivor three times higher than for OHCAs.
机译:背景技术与心脏骤停(CA)相关的重要社会经济负担,关于CA患者的长期结果和医疗保健相关费用的有限。本研究的目的是确定ICU治疗的CA患者的一年存活,神经系统结果和医疗保健成本。方法是2005年至2013年间在芬兰第三级医院ICU中治疗的成人Ca患者的单中心回顾性研究。患者的个人识别号码用于在几个全国范围的数据库之间交联数据,以获得一年生存率,神经系统结果,以及医疗保健相关的费用。针对心脏骤停位置分层的每只患者(OHCA?=?upounth-house acciac骤停,IHCA?=?所有院内心脏骤停,ICU-CA?和初始心律。通过将各种患者的所有医疗保健相关费用除以具有良好的神经系统结果的幸存者和幸存者的数量来估计成本效益。结果学习人群包括1,024名ICU治疗的CA患者。所有患者的成本总额为50,847,540欧元。在CA之后,58%的OHCAS,44%的IHCA和39%的ICU-CAS还活着。一年的幸存者97%的OHCAS,88%的IHCA,93%的ICU-CA有良好的神经系统结果。每项一年幸存者的有效成本为OHCAS为76,212欧元,IHCA€144,168,以及ICU-CAS的€239,468。每项一年幸存者的有效成本具有良好的神经系统结果为OHCAS的€81,196,IHCAS为164,442欧元,ICU-CAS为€257,207。结论ISION-ICU CA患者的一年生存率最低,每幸存者的有效成本比OHCAS高出三倍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号